romidepsin

Romidepsin is a small molecule anticancer agent classified as a histone deacetylase (HDAC) inhibitor. It is used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), particularly in patients who have received at least one prior systemic therapy. Romidepsin acts as a prodrug, becoming active inside cells where it binds to zinc-dependent HDAC enzymes, inhibiting their activity. This inhibition leads to increased acetylation of histones and other proteins, resulting in altered gene expression that can induce cell cycle arrest and apoptosis in cancer cells. Romidepsin was originally derived from the bacterium Chromobacterium violaceum.

Brand names

Istodax

Other names

depsipeptideantibiotic FR 901228